Skip to main content
Triangle logo TriangleGet started

Acalabrutinib (NCT07024706)

MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab: a one-minute explainerNCT070247061 min

Acalabrutinib trial for Chronic Lymphocytic Leukemia (CLL) (NCT07024706). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for patients aged 18–130 with relapsed CLL or SLL needing treatment. Their only prior treatment must be fixed-duration BTK-plus-BCL2 inhibition, with or without obinutuzumab, followed by at least two years of response.

The idea: oral acalabrutinib blocks B-cell growth signaling; venetoclax blocks a survival protein. Two acalabrutinib-only cycles precede 12 or 22 combination cycles, according to genetic risk. Each cycle lasts 28 days.

This phase 2 study plans 80 patients. AstraZeneca sponsors it, with four recruiting US sites. Researchers assess response and safety.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.